Carl Zeiss Meditec AG (XBUL:AFX) Beneish M-Score: -2.51 (As of Jul. 11, 2026)


XBUL:AFX Carl Zeiss Meditec AG XBUL:AFX
68 GF Score
Price лв42.34
GF Value лв105.79
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Beneish M-Score?

Carl Zeiss Meditec AG XBUL:AFX 68 Beneish M-Score is -2.51 as of Jul. 11, 2026. GuruFocus rates XBUL:AFX with a GF Score™ of 68/100 and a GF Value™ of лв105.79. The stock has 4 warning signs investors should review. Among 762 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks worse than 57.74% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.51 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Carl Zeiss Meditec AG's Beneish M-Score or its related term are showing as below:

XBUL:AFX' s Beneish M-Score Range Over the Past 10 Years
Min: -2.71   Med: -2.46   Max: -1.53
Current: -2.51

During the past 13 years, the highest Beneish M-Score of Carl Zeiss Meditec AG was -1.53. The lowest was -2.71. And the median was -2.46.


Carl Zeiss Meditec AG Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Beneish M-Score Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.62 -2.21 -2.44 -2.61 -2.43

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.61 -2.58 -2.66 -2.43 -2.51

XBUL:AFX vs ISRG, BDX, MDLN: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carl Zeiss Meditec AG Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's Beneish M-Score falls into.


XBUL:AFX
68GF Score
Carl Zeiss Meditec AG XBUL:AFX
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Carl Zeiss Meditec AG for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0949+0.528 * 1.0023+0.404 * 0.9736+0.892 * 1.1209+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9956+4.679 * -0.038939-0.327 * 0.9347
=-2.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was лв1,333 Mil.
Revenue was 924.639 + 1245.427 + 1071.927 + 1023.698 = лв4,266 Mil.
Gross Profit was 449.648 + 658.287 + 564.986 + 551.562 = лв2,224 Mil.
Total Current Assets was лв2,524 Mil.
Total Assets was лв6,754 Mil.
Property, Plant and Equipment(Net PPE) was лв681 Mil.
Depreciation, Depletion and Amortization(DDA) was лв0 Mil.
Selling, General, & Admin. Expense(SGA) was лв1,217 Mil.
Total Current Liabilities was лв1,079 Mil.
Long-Term Debt & Capital Lease Obligation was лв215 Mil.
Net Income was -9.702 + 102.822 + 55.339 + 82.864 = лв231 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = лв0 Mil.
Cash Flow from Operations was 33.065 + 286.096 + 111.54 + 63.628 = лв494 Mil.
Total Receivables was лв1,086 Mil.
Revenue was 868.458 + 1087.769 + 981.654 + 867.725 = лв3,806 Mil.
Gross Profit was 446.357 + 544.479 + 534.145 + 464.149 = лв1,989 Mil.
Total Current Assets was лв2,267 Mil.
Total Assets was лв6,368 Mil.
Property, Plant and Equipment(Net PPE) was лв664 Mil.
Depreciation, Depletion and Amortization(DDA) was лв0 Mil.
Selling, General, & Admin. Expense(SGA) was лв1,091 Mil.
Total Current Liabilities was лв1,068 Mil.
Long-Term Debt & Capital Lease Obligation was лв238 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1332.668 / 4265.691) / (1085.889 / 3805.606)
=0.312416 / 0.285339
=1.0949

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1989.13 / 3805.606) / (2224.483 / 4265.691)
=0.522684 / 0.521482
=1.0023

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2524.307 + 680.625) / 6754.337) / (1 - (2266.877 + 663.897) / 6367.922)
=0.5255 / 0.53976
=0.9736

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4265.691 / 3805.606
=1.1209

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 663.897)) / (0 / (0 + 680.625))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1217.11 / 4265.691) / (1090.612 / 3805.606)
=0.285325 / 0.28658
=0.9956

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((214.968 + 1079.248) / 6754.337) / ((237.881 + 1067.516) / 6367.922)
=0.191613 / 0.204996
=0.9347

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(231.323 - 0 - 494.329) / 6754.337
=-0.038939

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Carl Zeiss Meditec AG has a M-score of -2.45 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.51 mean?
Carl Zeiss Meditec AG (XBUL:AFX) has a Beneish M-Score of -2.51 as of Jul. 11, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Carl Zeiss Meditec AG and its competitors. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #440 out of 762 companies in the Medical Devices & Instruments industry, placing it in the top 57.7%.
Is Carl Zeiss Meditec AG's Beneish M-Score too high?
Carl Zeiss Meditec AG's current Beneish M-Score is -2.51. Based on the distribution chart, Carl Zeiss Meditec AG ranks #440 out of 762 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Carl Zeiss Meditec AG has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Beneish M-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #440 out of 762 companies for Beneish M-Score. This places Carl Zeiss Meditec AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Beneish M-Score is -2.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Carl Zeiss Meditec AG (XBUL:AFX) has a current Beneish M-Score of -2.51. The stock's GF Value™ is лв105.79, compared to a current price of лв42.34 — trading 60% below its estimated fair value. The current Beneish M-Score is -2.51. Carl Zeiss Meditec AG's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XBUL:AFX), the current Beneish M-Score is -2.51 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XBUL:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of лв42.34 is trading 60% below its estimated GF Value™ of лв105.79.

Key valuation signals for XBUL:AFX:

  • Beneish M-Score: -2.51
  • GF Value™: лв105.79 vs. price of лв42.34 (60% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the XBUL:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
68GF Score

Get the complete analysis for XBUL:AFX

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

лв42.34
Price
лв105.79
GF Value